HAIFA, Israel, October 26 /PRNewswire-FirstCall/ -- Cardio Vascular
Medical Device Corp. (OTC: CVSL), a leading developer of advanced
cardiovascular surgery technology, today released a brief shareholders update.
Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.
The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.
"Cardio Vascular Medical Device has developed a technology that provides several advantages over the current guidewires being employed in angioplasty procedures," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "And with well over 7 million angioplasties performed each year, the global annual potential addressable market in excess of $500 million."
Cardio Vascular Medical Device is working diligently to complete the development of the guidewire, in preparation for full commercial distribution.
Cardio Vascular Medical Device Corp. plans to keep public shareholders informed of all upcoming company developments.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated in the forward-looking statements. Cardio Vascular Medical Device Corp. public filings may be viewed at http://www.sec.gov.
Advertisement
Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.
Advertisement
The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.
"Cardio Vascular Medical Device has developed a technology that provides several advantages over the current guidewires being employed in angioplasty procedures," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "And with well over 7 million angioplasties performed each year, the global annual potential addressable market in excess of $500 million."
Cardio Vascular Medical Device is working diligently to complete the development of the guidewire, in preparation for full commercial distribution.
Cardio Vascular Medical Device Corp. plans to keep public shareholders informed of all upcoming company developments.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated in the forward-looking statements. Cardio Vascular Medical Device Corp. public filings may be viewed at http://www.sec.gov.
Contact: Alex Traiman, Media Relations, +1-646-863-9729;
Asher Zwebner, +972-54-464-6363, [email protected]
SOURCE Cardio Vascular Medical Device Corp.